Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients

We present two allogeneic hematopoietic cell transplantation recipients (HCTr) treated with pritelivir for acyclovir-resistant/refractory (r/r) HSV infection based on the expanded access program of the pritelivir manufacturer. Outpatient treatment with pritelivir was administered, with partial respo...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2023-04, Vol.67 (4), p.e0173222-e0173222
Main Authors: Bosetti, Davide, Bernardi, Chiara, Maulini, Marie, Giannotti, Federica, Mamez, Anne-Claire, Masouridi-Levrat, Stavroula, Chalandon, Yves, Neofytos, Dionysios
Format: Article
Language:English
Subjects:
Acyclovir - therapeutic use
Antiviral Agents
Challenging Clinical Case
Editor's Pick
Hematopoietic Stem Cell Transplantation - adverse effects
Herpes Simplex - chemically induced
Herpes Simplex - drug therapy
Humans
Salvage Therapy
Transplant Recipients
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present two allogeneic hematopoietic cell transplantation recipients (HCTr) treated with pritelivir for acyclovir-resistant/refractory (r/r) HSV infection based on the expanded access program of the pritelivir manufacturer. Outpatient treatment with pritelivir was administered, with partial response by week 1 of treatment and complete response by week 4 of treatment in both patients. No adverse events were noted. Pritelivir appears to be an effective and safe option for the management of acyclovir-r/r HSV infections in highly immunocompromised patients in an outpatient setting.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.01732-22